Cytomegalovirus Retinitis after Intravitreal Bevacizumab Injection in an Immunocompetent Patient.
- Author:
So Hyun BAE
1
;
Tae Wan KIM
;
Hum CHUNG
;
Jang Won HEO
Author Information
- Publication Type:Case Reports
- Keywords: Bevacizumab; Cytomegalovirus; Retinitis
- MeSH: Angiogenesis Inhibitors/administration & dosage/adverse effects; Antibodies, Monoclonal, Humanized/administration & dosage/*adverse effects; Cytomegalovirus/genetics; Cytomegalovirus Retinitis/diagnosis/*etiology/immunology; DNA, Viral/analysis; Diagnosis, Differential; Female; Humans; Immunocompetence/*drug effects; Intravitreal Injections; Macular Edema/diagnosis/*drug therapy; Middle Aged; Polymerase Chain Reaction; Vascular Endothelial Growth Factor A/antagonists & inhibitors
- From:Korean Journal of Ophthalmology 2013;27(1):61-63
- CountryRepublic of Korea
- Language:English
- Abstract: We report a case of cytomegalovirus (CMV) retinitis after intravitreal bevacizumab injection. A 61-year-old woman with diabetic macular edema developed dense vitritis and necrotizing retinitis 3 weeks after intravitreal bevacizumab injection. A diagnostic vitrectomy was performed. The undiluted vitreous sample acquired by vitrectomy was analyzed by polymerase chain reaction and culture. Polymerase chain reaction of the vitreous was positive for CMV DNA. Other laboratory results did not show evidence of other infectious retinitis and systemic immune dysfunction. Human immunodeficiency virus antibodies were also negative. After systemic administration of ganciclovir, retinitis has resolved and there has been no recurrence of retinitis during the follow-up period of 12 months. Ophthalmologists should be aware of potential risk for CMV retinitis after intravitreal bevacizumab injection.
